Asarina Pharma (Buy, TP: SEK61.00) - Takeaways from R&D day
The aim of today’s R&D day was to educate the market on the four key metrics used to evaluate the efficacy of Sepranolone. Top-line results are expected at end-April. An investor day is planned for 4 May, to dive into the results. The high unmet medical need was highlighted by a PMDD patient. We remain optimistic on the outcome and reiterate our BUY and SEK61 target price.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.